Selected research
Industry Research
Hemoderivative Industry Research Report 2026
Market perspective
The global Hemoderivative market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hemoderivative is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hemoderivative is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hemoderivative is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hemoderivative include CSL, Grifols, Kedrion, LFB Group, Octapharma, CBPO, Boya Bio, Hualan Bio and Shanghai RAAS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hemoderivative market in terms of revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hemoderivative Market by Company
CSL
Grifols
Kedrion
LFB Group
Octapharma
CBPO
Boya Bio
Hualan Bio
Shanghai RAAS
Shuanglin Bio
Tiantan Bio
Weiguang Bio
Takeda
Yuanda Shuyang
Hemoderivative Segment by Type
Coagulation Factors
Immunoglobulins
Albumin
Others
Hemoderivative Segment by Application
Therapeutics
Excipient
Other
Hemoderivative Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemoderivative market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemoderivative and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemoderivative.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hemoderivative manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hemoderivative by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hemoderivative in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Coagulation Factors
- Immunoglobulins
- Albumin
- Others
Applications
- Therapeutics
- Excipient
- Other
Companies covered
- CSL
- Grifols
- Kedrion
- LFB Group
- Octapharma
- CBPO
- Boya Bio
- Hualan Bio
- Shanghai RAAS
- Shuanglin Bio
- Tiantan Bio
- Weiguang Bio
- Takeda
- Yuanda Shuyang
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hemoderivative Market Size (2021-2032)
- 2.2.2 Global Hemoderivative Sales (2021-2032)
- 2.2.3 Global Hemoderivative Market Average Price (2021-2032)
- 2.3 Hemoderivative by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Coagulation Factors
- 2.3.3 Immunoglobulins
- 2.3.4 Albumin
- 2.3.5 Others
- 2.4 Hemoderivative by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Therapeutics
- 2.4.3 Excipient
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hemoderivative Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hemoderivative Sales (t) of Manufacturers (2021-2026)
- 3.3 Global Hemoderivative Revenue of Manufacturers (2021-2026)
- 3.4 Global Hemoderivative Average Price by Manufacturers (2021-2026)
- 3.5 Global Hemoderivative Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hemoderivative, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hemoderivative, Product Type & Application
- 3.8 Global Manufacturers of Hemoderivative, Established Date
- 3.9 Global Hemoderivative Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSL
- 4.1.1 CSL Company Information
- 4.1.2 CSL Business Overview
- 4.1.3 CSL Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSL Hemoderivative Product Portfolio
- 4.1.5 CSL Recent Developments
- 4.2 Grifols
- 4.2.1 Grifols Company Information
- 4.2.2 Grifols Business Overview
- 4.2.3 Grifols Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Grifols Hemoderivative Product Portfolio
- 4.2.5 Grifols Recent Developments
- 4.3 Kedrion
- 4.3.1 Kedrion Company Information
- 4.3.2 Kedrion Business Overview
- 4.3.3 Kedrion Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Kedrion Hemoderivative Product Portfolio
- 4.3.5 Kedrion Recent Developments
- 4.4 LFB Group
- 4.4.1 LFB Group Company Information
- 4.4.2 LFB Group Business Overview
- 4.4.3 LFB Group Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 LFB Group Hemoderivative Product Portfolio
- 4.4.5 LFB Group Recent Developments
- 4.5 Octapharma
- 4.5.1 Octapharma Company Information
- 4.5.2 Octapharma Business Overview
- 4.5.3 Octapharma Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Octapharma Hemoderivative Product Portfolio
- 4.5.5 Octapharma Recent Developments
- 4.6 CBPO
- 4.6.1 CBPO Company Information
- 4.6.2 CBPO Business Overview
- 4.6.3 CBPO Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 CBPO Hemoderivative Product Portfolio
- 4.6.5 CBPO Recent Developments
- 4.7 Boya Bio
- 4.7.1 Boya Bio Company Information
- 4.7.2 Boya Bio Business Overview
- 4.7.3 Boya Bio Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Boya Bio Hemoderivative Product Portfolio
- 4.7.5 Boya Bio Recent Developments
- 4.8 Hualan Bio
- 4.8.1 Hualan Bio Company Information
- 4.8.2 Hualan Bio Business Overview
- 4.8.3 Hualan Bio Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hualan Bio Hemoderivative Product Portfolio
- 4.8.5 Hualan Bio Recent Developments
- 4.9 Shanghai RAAS
- 4.9.1 Shanghai RAAS Company Information
- 4.9.2 Shanghai RAAS Business Overview
- 4.9.3 Shanghai RAAS Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Shanghai RAAS Hemoderivative Product Portfolio
- 4.9.5 Shanghai RAAS Recent Developments
- 4.10 Shuanglin Bio
- 4.10.1 Shuanglin Bio Company Information
- 4.10.2 Shuanglin Bio Business Overview
- 4.10.3 Shuanglin Bio Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Shuanglin Bio Hemoderivative Product Portfolio
- 4.10.5 Shuanglin Bio Recent Developments
- 4.11 Tiantan Bio
- 4.11.1 Tiantan Bio Company Information
- 4.11.2 Tiantan Bio Business Overview
- 4.11.3 Tiantan Bio Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Tiantan Bio Hemoderivative Product Portfolio
- 4.11.5 Tiantan Bio Recent Developments
- 4.12 Weiguang Bio
- 4.12.1 Weiguang Bio Company Information
- 4.12.2 Weiguang Bio Business Overview
- 4.12.3 Weiguang Bio Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Weiguang Bio Hemoderivative Product Portfolio
- 4.12.5 Weiguang Bio Recent Developments
- 4.13 Takeda
- 4.13.1 Takeda Company Information
- 4.13.2 Takeda Business Overview
- 4.13.3 Takeda Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Takeda Hemoderivative Product Portfolio
- 4.13.5 Takeda Recent Developments
- 4.14 Yuanda Shuyang
- 4.14.1 Yuanda Shuyang Company Information
- 4.14.2 Yuanda Shuyang Business Overview
- 4.14.3 Yuanda Shuyang Hemoderivative Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Yuanda Shuyang Hemoderivative Product Portfolio
- 4.14.5 Yuanda Shuyang Recent Developments
5 Global Hemoderivative Market Scenario by Region
- 5.1 Global Hemoderivative Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hemoderivative Sales by Region: 2021-2032
- 5.2.1 Global Hemoderivative Sales by Region: 2021-2026
- 5.2.2 Global Hemoderivative Sales by Region: 2027-2032
- 5.3 Global Hemoderivative Revenue by Region: 2021-2032
- 5.3.1 Global Hemoderivative Revenue by Region: 2021-2026
- 5.3.2 Global Hemoderivative Revenue by Region: 2027-2032
- 5.4 North America Hemoderivative Market Facts & Figures by Country
- 5.4.1 North America Hemoderivative Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hemoderivative Sales by Country (2021-2032)
- 5.4.3 North America Hemoderivative Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Hemoderivative Market Facts & Figures by Country
- 5.5.1 Europe Hemoderivative Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hemoderivative Sales by Country (2021-2032)
- 5.5.3 Europe Hemoderivative Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Hemoderivative Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hemoderivative Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hemoderivative Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hemoderivative Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hemoderivative Market Facts & Figures by Country
- 5.7.1 South America Hemoderivative Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hemoderivative Sales by Country (2021-2032)
- 5.7.3 South America Hemoderivative Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Hemoderivative Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hemoderivative Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hemoderivative Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hemoderivative Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Hemoderivative Sales by Type (2021-2032)
- 6.1.1 Global Hemoderivative Sales by Type (2021-2032) & (t)
- 6.1.2 Global Hemoderivative Sales Market Share by Type (2021-2032)
- 6.2 Global Hemoderivative Revenue by Type (2021-2032)
- 6.2.1 Global Hemoderivative Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hemoderivative Revenue Market Share by Type (2021-2032)
- 6.3 Global Hemoderivative Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hemoderivative Sales by Application (2021-2032)
- 7.1.1 Global Hemoderivative Sales by Application (2021-2032) & (t)
- 7.1.2 Global Hemoderivative Sales Market Share by Application (2021-2032)
- 7.2 Global Hemoderivative Revenue by Application (2021-2032)
- 7.2.1 Global Hemoderivative Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hemoderivative Revenue Market Share by Application (2021-2032)
- 7.3 Global Hemoderivative Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hemoderivative Value Chain Analysis
- 8.1.1 Hemoderivative Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hemoderivative Production Mode & Process
- 8.2 Hemoderivative Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hemoderivative Distributors
- 8.2.3 Hemoderivative Customers
9 Global Hemoderivative Analyzing Market Dynamics
- 9.1 Hemoderivative Industry Trends
- 9.2 Hemoderivative Industry Drivers
- 9.3 Hemoderivative Industry Opportunities and Challenges
- 9.4 Hemoderivative Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst